Moleculin Provides Additional Comments Regarding Trading Halt
HOUSTON, May 11, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that since the May 1st,...
Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020
HOUSTON, May 8, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its intention to adjourn its 2020...
Moleculin Announces Trading Halt
HOUSTON, May 4, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced securities of the Company have been...
Moleculin to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference
HOUSTON, April 29, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and...
Moleculin Approved to Accelerate European Clinical Trial
Regulatory authorization doubles dose escalation in Annamycin AML trialHOUSTON, April 28, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced...
Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team
Dr. Richard Whitley, a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery Joins Moleculin's Science Advisory BoardHOUSTON, April 22, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical...
Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2 by 100%HOUSTON, April 20, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...
Moleculin to Host Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate Today
Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2 by 100%HOUSTON, April 16, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...
Moleculin Announces Leading Virologist Joins Development Team
Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2HOUSTON, April 15, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...
Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate
Follows discovery that active compound in WP1122 reduces in vitro replication of SARS-CoV-2 by 100%HOUSTON, April 14, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...